

## PRINCIPAL INVESTIGATOR REVIEW OF ONGOING RESEARCH REPORT

1. PI/SIT	TE ADI	MINISTI	RATIV	E INFORM	OITAN	V				
Name of P	rincipal l	nvestigato	or:							
Site / Clinic	c / Comp	any Name	e:							
Site Conta	ct Perso	n for IRB I	ssues:							
Contact's Phone ( )			-		Co	ntact's Fax	(	) -		
Contact's I	Email Ad	ldress:								
Street:										
City:					Province / State:					
Country:					Postal /	Zip Code:				
2. STUD	Y IDE	NTIFIC	ATION							
Sponsor o	f the Res	search:								
Protocol N	Protocol Number:				(If th	ere is no Proto	ocol Num	ber check	here: 🔲 )	
Protocol T	itle:				'					
3. STUD	VENE	OLMEI	NT.							
Study i	s dorman Funding Accrual Other: _ ent open ent close st Particip ent close st Particip	t: g issues problems ( and is at: _ d – experiment enrolle d – follow-upant enrolle	see recru per nental pro d: DD p only. N	uitment difficult  cent of projected according to the continuation of the continuation	ed enrolme	ocedures.				
First Partic	ipant In:	/_ DD	M M	YYYY		ected Date of Iment Comple		//	/ MM YY	YY
Total number in this Stud			enrolled			Total numb withdrawn		•	Site:	
If any, please provide reasons for Participant withdrawal:  Lack of Efficacy Adverse Event(s)  Lost to Follow-Up (unable to contact Participant)  Withdrew consent (Specify if any reason given):  Other (Specify):										
Were there ar	ny difficult	ies recruitir	ng or reta	ining Participar	nts in this	Study?			☐ Yes	s 🔲 No
If yes, please	explain:									



4. STUDY PROTOCOL									
What is the date of the Study Protocol currently in use, including any Amendments?									
Study Protocol://	Last Amendment:								
DD MM YYY	(Y DD	MM YYYY							
5. INFORMED CONSENT DOCUME	NTATION								
Date of the Informed Consent Documentation currently in use:  DD MM YYYY									
Was the Informed Consent Document duly signed by the Study Participant and the Investigator or his delegate prior to any Study related procedures?									
Were copies of the Informed Consent Document pr	☐ Yes ☐ No								
Were any problems encountered while communicating the Study to the Study Participants?									
If yes, please list problem categories:  ☐ Informed Consent Document is too technical ☐ Informed Consent Document is too long ☐ Same questions are constantly asked by Study Participants ☐ Other (please explain):									
6. RECRUITMENT MATERIALS									
Are there any Recruitment Materials used in this Study?									
If yes, what is the date of the following Recruitment Materials currently in use?	□ Poster	DD   MM   YYYY   DD   MM   YYYYY   MM   YYYYY   DD   MM   YYYYY   MM   YYYYY   DD   MM   YYYYY   MM   YYYYY   DD   MM   YYYYY   MM							
7. INVESTIGATORS									
Are there any changes in the duties of the Investigator	rs participating in the Study at this Site?	☐ Yes ☐ No							
If yes, please provide details:									
Does the Principal Investigator have any new confliction Study at his/her Site?	Yes No								
If yes, please provide details:									
Has the Principal Investigator been audited for any study by Health Canada, the FDA or OHRP since the last approval of the Study at this Site?									
If yes, please provide details and/or a copy of the Aud	it Report as soon as possible:								
Are there any current investigations or charges involving the Principal or Sub-Investigator(s)?									
If yes, please provide details:									
Are all Investigators participating in the Study at this S  If no, please provide their Curriculum Vitae and Medical License		Yes No							
I have provided an updated copy of Current Medical Licenses of all Investigators participating in the Study at this Site for the upcoming year.									

www.VeritasIRB.com Version: January 9, 2015 Page 2 of 3



8. SAFETY AND COMPLAINTS			
Since the last IRB review, have there been any Unanticipated Problems (including Adverse Events) involving risks to Participants or others that <u>have not</u> yet been reported to the IRB?	□Y	es	□No
If yes, attach a summary describing the Unanticipated Problems involving risks to Participants or others.			
Since the last IRB review, have there been any significant Protocol Deviations that <u>have not</u> yet been reported to the IRB?	□Y	es	□No
If yes, attach a summary describing the nature of the significant Protocol Deviations.			
Have there been any Protocol Deviations that do not require reporting to the IRB but are repeating o are of similar nature?		es	□No
If yes, attach a summary describing the nature of the Protocol Deviations.			
Since the last IRB review, have any Participants or others complained to the Site about the research?	□Y	es	□No
If yes, attach a summary describing the number and nature of the complaints.			
How many unexpected and related Serious Adverse Events were experienced in this Study at this Site in total?			
How many unexpected and related Serious Adverse Events were experienced in this Study at this Site since last approval?			
9. STUDY MONITORING			
Since the last IRB review, did the Sponsor monitor the Study?	□Y	es	☐ No
If yes, what is the number of monitoring visits to this Site?			
In the opinion of the Principal Investigator, have the risks or potential benefits of this research changed?	□Y	es	□No
If yes, attach a summary description of those changes.			
I certify that I have submitted all the required documentation and that the above information is		and	
truthful to the best of my knowledge.  Print Name	s accurate a		
truthful to the best of my knowledge.	s accurate a		

www.VeritasIRB.com Version: January 9, 2015 Page 3 of 3